Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock


Monocyte CD14 and HLA-DR expression increases with disease duration and severity in amyotrophic lateral sclerosis.


Objective: To investigate changes in immune markers and frequencies throughout disease progression in patients with amyotrophic lateral sclerosis (ALS). Methods: In this longitudinal study, serial blood samples were collected from 21 patients with ALS over a time period of up to 16 months. Flow cytometry was used to quantitate CD14, HLA-DR, and CD16 marker expression on monocyte subpopulations and neutrophils, as well as their cell population frequencies. A Generalized Estimating Equation model was used to assess the association between changes in these immune parameters and disease duration and the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Results: CD14 expression on monocyte subpopulations increased with both disease duration and a decrease in ALSFRS-R score in patients with ALS. HLA-DR expression on monocyte subpopulations also increased with disease severity and/or duration. The expression of CD16 did not change relative to disease duration or ALSFRS-R. Finally, patients had a reduction in non-classical monocytes and an increase in the classical to non-classical monocyte ratio throughout disease duration. Conclusion: The progressive immunological changes observed in this study provide further support that monocytes are implicated in ALS pathology. Monocytic CD14 and HLA-DR surface proteins may serve as a therapeutic target or criteria for the recruitment of patients with ALS into clinical trials for immunomodulatory therapies.

Authors: Mcgill RB, Steyn FJ, Ngo ST, Thorpe KA, Heggie S, Henderson RD, Mccombe PA, Woodruff TM,
Journal: Amyotroph Lateral Scler Frontotemporal Degener;2021Aug16 1-8. doi:10.1080/21678421.2021.1964531
Year: 2021
PubMed: PMID: 34396845 (Go to PubMed)